Statins for the prevention of contrast-induced nephropathy after coronary angiography/percutaneous interventions: A meta-analysis of randomized controlled trials

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 20, Issue 2, 2015, Pages 181-192

  Liu, Yuan Hui ^a,b   Liu, Yong ^b   Duan, Chong Yang ^a   Tan, Ning ^b   Chen, Ji Yan ^b   Zhou, Ying Ling ^b   Li, Li Wen ^b   He, Peng Cheng ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

chronic kidney disease; contrast induced nephropathy; coronary angiography; meta analysis; percutaneous interventions; statins

Indexed keywords

ATORVASTATIN; CONTRAST MEDIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ANGIOCARDIOGRAPHY; ARTICLE; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; CLINICAL RESEARCH; COCHRANE LIBRARY; CONTRAST INDUCED NEPHROPATHY; CONTROLLED CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; EMBASE; HIGH RISK PATIENT; HUMAN; INCIDENCE; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PUBLISHING; WEB OF SCIENCE; ADULT; AGED; CHEMICALLY INDUCED; CORONARY ANGIOGRAPHY; KIDNEY DISEASES; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; AGED; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84922620743     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248414549462     Document Type: Article

References (43)

1. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008 ; 51 (15). 1419-1428
2. Maioli M, Toso A, Leoncini M, Gallopin M, Musilli N, Bellandi F. Persistent renal damage after contrast-induced acute kidney injury: incidence, evolution, risk factors, and prognosis. Circulation. 2012 ; 125 (25). 3099-3107
3. Dangas G, Iakovou I, Nikolsky E, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005 ; 95 (1). 13-19
4. Stacul F, van der Molen AJ, Reimer P, et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol. 2011 ; 21 (12). 2527-2541
5. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011 ; 58 (24). e44 - e122
6. Ongini E, Impagnatiello F, Bonazzi A, et al. Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties. Proc Natl Acad Sci U S A. 2004 ; 101 (22). 8497-8502
7. Wassmann S, Faul A, Hennen B, Scheller B, Böhm M, Nickenig G. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res. 2003 ; 93 (9). e98 - e103
8. McCullough PA, Adam A, Becker CR, et al. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol. 2006 ; 98 (6A). 5K - 13
9. Persson PB, Tepel M. Contrast medium-induced nephropathy: the pathophysiology. Kidney Int Suppl. 2006 ; (100). S8 - S10
10. Wong PC, Li Z, Guo J, Zhang A. Pathophysiology of contrast-induced nephropathy. Int J Cardiol. 2012 ; 158 (2). 186-192
11. Zhang T, Shen LH, Hu LH, He B. Statins for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Nephrol. 2011 ; 33 (4). 344-351
12. Zhang L, Zhang L, Lu Y, et al. Efficacy of statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis of randomised controlled trials. Int J Clin Pract. 2011 ; 65 (5). 624-630
13. Pappy R, Stavrakis S, Hennebry TA, Abu-Fadel MS. Effect of statin therapy on contrast-induced nephropathy after coronary angiography: a meta-analysis. Int J Cardiol. 2011 ; 151 (3). 348-353
14. Zhou Y, Yuan WJ, Zhu N, Wang L. Short-term, high-dose statins in the prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Clin Nephrol. 2011 ; 76 (6). 475-483
15. Li Y, Liu Y, Fu L, Mei C, Dai B. Efficacy of short-term high-dose statin in preventing contrast-induced nephropathy: a meta-analysis of seven randomized controlled trials. PLoS One. 2012 ; 7 (4). e34450
16. Zhang BC, Li WM, Xu YW. High-dose statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis. Can J Cardiol. 2011 ; 27 (6). 851-858
17. Li W, Fu X, Wang Y, et al. Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention. Cardiology. 2012 ; 122 (3). 195-202
18. Quintavalle C, Fiore D, De Micco F, et al. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation. 2012 ; 126 (25). 3008-3016
19. Leoncini M, Toso A, Maioli M, Tropeano F, Villani S, Bellandi F. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: results from the PRATO-ACS study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). J Am Coll Cardiol. 2014 ; 63 (1). 71-79
20. Han Y, Zhu G, Han L, et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol. 2014 ; 63 (1). 62-70
21. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996 ; 17 (1). 1-12
22. Verhagen AP, de Vet HC, de Bie RA, et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol. 1998 ; 51 (12). 1235-1241
23. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003 ; 327 (7414). 557-560
24. Chen GL, JZ Su. [Atorvastatin attenuated contrast induced renal function damage]. Zhonghua Xin Xue Guan Bing Za Zhi. 2009 ; 37 (5). 389-393
25. Acikel S, Muderrisoglu H, Yildirir A, et al. Prevention of contrast-induced impairment of renal function by short-term or long-term statin therapy in patients undergoing elective coronary angiography. Blood Coagul Fibrinolysis. 2010 ; 21 (8). 750-757
26. Patti G, Ricottini E, Nusca A, et al. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty - contrast-induced nephropathy] trial. Am J Cardiol. 2011 ; 108 (1). 1-7
27. Ozhan H, Erden I, Ordu S, et al. Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Angiology. 2010 ; 61 (7). 711-714
28. Jo SH, Koo BK, Park JS, et al. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial-a randomized controlled study. Am Heart J. 2008 ; 155: 491-499
29. Toso A, Maioli M, Leoncini M, et al. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am J Cardiol. 2010 ; 105: 288-292
30. Ichiki T, Takeda K, Tokunou T, et al. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2001 ; 21 (12). 1896-1901
31. Almuti K, Rimawi R, Spevack D, et al. Effects of statins beyond lipid lowering: potential for clinical benefits. Int J Cardiol. 2006 ; 109 (1). 7-15
32. Gao F, Zhou YJ, Zhu X, et al. C-reactive protein and the risk of contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention. Am J Nephrol. 2011 ; 34 (3). 203-210
33. Liu YH, Liu Y, Tan N, et al. Predictive value of GRACE risk scores for contrast-induced acute kidney injury in patients with ST-segment elevation myocardial infarction before undergoing primary percutaneous coronary intervention. Int Urol Nephrol. 2014 ; 46 (2). 417-426
34. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 ; 359 (21). 2195-2207
35. Singh I, Rajagopalan S, Srinivasan A, et al. Preoperative statin therapy is associated with lower requirement of renal replacement therapy in patients undergoing cardiac surgery: a meta-analysis of observational studies. Interact Cardiovasc Thorac Surg. 2013 ; 17 (2). 345-352
36. McCullough PA, Sandberg KR. Epidemiology of contrast-induced nephropathy. Rev Cardiovasc Med. 2003 ; 4: S3 - S9
37. Davidson CJ, Hlatky M, Morris KG, et al. Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization. A prospective trial. Ann Intern Med. 1989 ; 110 (2). 119-124
38. Reddan D, Laville M, Garovic VD. Contrast-induced nephropathy and its prevention: What do we really know from evidence-based findings?. J Nephrol. 2009 ; 22 (3). 333-351
39. McCullough PA. Radiocontrast-induced acute kidney injury. Nephron Physiol. 2008 ; 109 (4). p61 - p72
40. Qu HY, Xiao YW, Jiang GH, et al. Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia. Pharm Res. 2009 ; 26 (4). 958-964
41. Toth PP, Dayspring TD. Drug safety evaluation of rosuvastatin. Expert Opin Drug Saf. 2011 ; 10 (6). 969-986
42. Herregods MC, Daubresse JC, Michel G, et al. Discovery Belux: comparison of rosuvastatin with atorvastatin in hypercholesterolaemia. Acta Cardiol. 2008 ; 63 (4). 493-499
43. Kaya A, Kurt M, Tanboga IH, et al. Rosuvastatin versus atorvastatin to prevent contrast induced nephropathy in patients undergoing primary percutaneous coronary intervention (ROSA-cIN trial). Acta Cardiol. 2013 ; 68 (5). 489-494